Phase II dose finding trial of oral testosterone undecanoate [LPCN 1021] in hypogonadal men
Latest Information Update: 11 Feb 2014
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- 11 Feb 2014 New trial record
- 10 Feb 2014 The starting dose selected for the phase III SOAR trial was selected based on results of this trial (primary endpoint met and no significant adverse events), according to a Lipocine media release.